

P. Thomas Bright

Associate

Richmond

thomas.bright@troutman.com

D 804.697.2299



OVERVIEW

Thomas represents public and private companies on a wide range of matters, including securities issuances, securities law compliance, periodic reporting, mergers and acquisitions and general corporate governance. He also regularly advises clients with respect to the Corporate Transparency Act.

Thomas maintains an active pro bono practice. He frequently counsels aspiring nonprofit organizations from formation through application for recognition of federal tax exemption, and with ongoing governance and related matters.

REPRESENTATIVE MATTERS

- Represented a publicly traded specialty pharmaceutical company in its \$200 million private investment in public equity (PIPE) transaction.
- Represented a publicly traded specialty pharmaceutical company in its establishment of an at-the-market program for selling its common stock.
- Represented a publicly traded real estate investment trust in its \$550 million underwritten public offering of senior notes.
- Represented a UK-based trenchless rehabilitation manufacturer in the sale of its U.S. business.
- Represented a publicly traded owner/operator of franchised businesses in a go-private transaction.
- Represented a private equity portfolio company in the acquisition of drug testing services businesses.
- Represented private equity fund portfolio companies in connection with various day to day business matters, including corporate governance, financing, contract, and executive compensation matters.

TOP AREAS OF FOCUS

- Corporate

ALL AREAS OF FOCUS

- [Corporate](#)
- [Corporate Transparency Act](#)
- [Financial Services](#)
- [Private Equity](#)

EDUCATION AND CERTIFICATIONS

EDUCATION

- University of Virginia School of Law, J.D., 2020
- Emory University, B.A., *with highest honors*, 2011, Phi Beta Kappa

BAR ADMISSIONS

- Virginia

SPEAKING ENGAGEMENTS

- Speaker, [Troutman Pepper's 2024 Public Company Seminar](#), October 24, 2024.

PUBLICATIONS

- Co-author, "[Practical Implications of the Interim Final Rule for BOI Reporting Under the CTA](#)," *Troutman Pepper Locke*, April 22, 2025.
- Co-author, "[CTA Significantly Amended by Interim Final Rule](#)," *Troutman Pepper Locke*, March 25, 2025.
- Co-author, "[Summary Overview: 3 Steps to CTA Compliance](#)," *Troutman Pepper*, November 26, 2024.
- Co-author, "[Upcoming Corporate Transparency Act Compliance Deadlines](#)," *Troutman Pepper*, October 16, 2024.
- Co-author, "[FinCEN Publishes Updated FAQs Regarding CTA Filings for Dissolved Entities and Withdrawn Foreign Entities](#)," *Troutman Pepper*, September 13, 2024.
- Co-author, "[FinCEN Clarifies CTA Reporting Requirements for Entities That No Longer Exist](#)," *Troutman Pepper*, July 10, 2024.
- Co-author, "[FinCEN Issues Final Rule on Use of Entity FinCEN Identifiers to Fulfill BOI Reporting Requirements Under the CTA](#)," *Troutman Pepper*, November 15, 2023.
- Co-author, "[Notable Requirements Under FinCEN's Final Rule Implementing the Corporate Transparency Act Reporting Framework](#)," *Troutman Pepper*, December 2, 2022.
- Co-author, "[SEC Proposes Amendments to Certain Bases to Exclude Shareholder Proposals Under Rule 14a-8](#)," *Troutman Pepper*, July 19, 2022.
- Co-author, "[Comptroller of the Currency Cites TBTF Risks at Large Regional Banks](#)," *Troutman Pepper*, April 20, 2022.
- Co-author, "[CBA Requests Increased CFPB Supervision of Fintechs Via the Larger Participant Rule](#)," *Troutman Pepper*, October 22, 2021.
- Co-author, "[The Federal Reserve, FDIC, and OCC Publish Proposed Interagency Guidance on Third-Party Relationships: Risk Management](#)," *Troutman Pepper*, July 29, 2021.
- Co-author, "[SAFE Banking Act of 2021 to Provide Cannabis Industry Access to Financial Services, but Obstacles Remain](#)," *Troutman Pepper*, April 28, 2021.